The FDA will convene an advisory committee meeting in September to review Grail’s controversial multi-cancer test after it failed to meet the primary endpoint in a large randomized UK trial. The upcoming discussion keeps pressure on the company and on the evidentiary bar for earlier detection assays. The decision reflects the regulator’s scrutiny of both clinical performance and downstream benefit claims for blood-based screening tests, as skepticism around the trial design and impact continues across stakeholders.